Read + Share
Normann LS, Haugen MH, Hongisto V, Aure MR, et al. High-throughput screen in vitro identifies dasatinib as a candidate for
combinatorial treatment with HER2-targeting drugs in breast cancer. PLoS One 2023;18:e0280507.
PMID: 36706086
|
 |
|
Normann LS, Haugen MH, Hongisto V, Aure MR, et al. High-throughput screen in vitro identifies dasatinib as a candidate for
combinatorial treatment with HER2-targeting drugs in breast cancer. PLoS One 2023;18:e0280507.
PMID: 36706086
|
|
|
|